Zydus Lifesciences is currently trading at RS. 973.90, up by 2.85 points or 0.29% from its previous closing of RS. 971.05 on the BSE.

The stock opened at RS. 974.80 and recorded a high of RS. 976.70 and a low of RS. 961.60 during the session. So far, 5903 shares have been traded on the counter.

A BSE group 'A' stock with a face value of RS. 1, Zydus touched its 52-week high of RS. 1323.90 on August 9, 2024, and a 52-week low of RS. 797.05 on April 7, 2025. Over the past week, the scrip traded between RS. 979.90 and RS. 951.40. The company’s current market capitalization stands at RS. 97841.16 crore.

Promoter holding in the company is at 74.99%, while institutional and non-institutional investors hold 18.26% and 6.74% respectively.

In a key development, Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets in strengths of 140 mg, 280 mg, and 420 mg. These are the generic equivalents of Imbruvica tablets and are indicated for treating adult patients with Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL) with 17p deletion, and Waldenstrom's Macroglobulinemia (WM).

The tablets will be manufactured at the company’s SEZ facility in Ahmedabad. Ibrutinib tablets recorded annual sales of $2148.9 million in the U.S. market as per IQVIA MAT data for May 2025.

With this, Zydus now holds 420 approvals and has filed approximately 484 Abbreviated New Drug Applications (ANDAs) since FY 2003-04.

Zydus Lifesciences, formerly Cadila Healthcare, is an integrated pharmaceutical company based in India, covering the entire pharmaceutical value chain—from research and development to production, marketing, and distribution.